Spots Global Cancer Trial Database for CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome

Official Title: A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Myelodysplastic Syndrome

Study ID: NCT05617625

Conditions

Myelodysplastic Syndromes

Graft Vs Host Disease

Graft-versus-host-disease

Interventions

Busulfan

Melphalan

Fludarabine

CliniMACS CD34+ enriched, T-cell depleted peripheral blood stem cell (PBSC)

Study Description

Brief Summary: This study will evaluate whether processing blood stem cell transplants using an investigational device (the CliniMACS system) results in fewer complications for patients who undergo transplant to treat a blood malignancy (cancer) or blood disorder. The CliniMACS system will be used to remove immune T-cells from the transplant donor's blood. Immune T-cells contribute to graft versus host disease (GVHD) - a serious complication that can happen after transplant. GVHD occurs when a patient's immune system attacks the donor's cells. The study aims to reduce the number of the donor immune T-cells thereby preventing or reducing the severity of GVHD.

Detailed Description: